SELLAS Life Sciences Group Inc. (SLS), a late-stage clinical biopharmaceutical company, has key milestones ahead in the coming weeks.
The company's lead product candidate is Galinpepimut-S (GPS), licensed from Memorial Sloan Kettering Cancer Center, and it targets the WT1 protein, which is present in an array of tumor types.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com